Tone mix
Week by week 52 weeks
Share of Nektar Therapeutics's 205 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of May 11, 2026 · tone +90HC Wainwright Issues Positive Forecast for NKTR Earnings+92
- Week of Jul 20, 2026 · tone +1005 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & More+87
- Week of Sep 8, 2025 · tone +100Why Nektar Therapeutics Rippled Higher This Week+86
- Week of Sep 22, 2025 · tone +100Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today+75
- Week of Oct 6, 2025 · tone +100Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September+61
- Week of Feb 9, 2026 · tone +97Nektar Therapeutics Shares Surge 42% On Positive Phase 2b Atopic Dermatitis Data+55
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Nektar Therapeutics in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | 0 |
| Last 30 sessions | 15 | +13 |
| Last 90 sessions | 39 | +13 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, October 28, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 1 outletNektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial MarketsNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets | www.prnewswire.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 2 outletsNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | www.prnewswire.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.tickerreport.com · 1 outletNektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink Partners | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 14, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletNektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by UBS GroupPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by UBS Group | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
3 headlines, average tone 0: 0 positive, 3 neutral and 0 negative. Showing all 3.
- www.dailypolitical.com · 1 outletCritical Comparison: Nektar Therapeutics (NASDAQ:NKTR) versus Maze Therapeutics (NASDAQ:MAZE)Neutral
- www.themarketsdaily.com · 1 outletNektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNeutral
- www.tickerreport.com · 1 outletContrasting Nektar Therapeutics (NASDAQ:NKTR) and Cardiff Oncology (NASDAQ:CRDF)Neutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Critical Comparison: Nektar Therapeutics (NASDAQ:NKTR) versus Maze Therapeutics (NASDAQ:MAZE) | www.dailypolitical.com | 1 | Neutral |
| Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink Partners | www.themarketsdaily.com | 1 | Neutral |
| Contrasting Nektar Therapeutics (NASDAQ:NKTR) and Cardiff Oncology (NASDAQ:CRDF) | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Nektar Therapeutics, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.